Studies showing that hormone replacement therapy can raise the risk of heart disease, cancer and blood clots have knocked U.S. prescriptions for the drugs back to where they were nine years ago, according to a report in this week's issue of the Journal of the American Medical Association.
This suggests that doctors "may rapidly abandon well-established therapies when studies demonstrate harm" and that "patients also played a major role" in the reversal, Stanford University School of Medicine researchers noted.
The authors found that the number of hormone therapy prescriptions rose to 90 million in 1999 from 58 million in 1995 and remained stable through June 2002. Estrogen/progestin combinations, primarily Wyeth's Prempro, accounted for most of the growth.
Study findings released starting in July 2002 triggered an avalanche of bad news about the therapy, and a sharp drop in prescriptions followed.
If prescription rates seen through July 2003 continue, the report said, there were probably 57 million written last year, close to the rate in 1995.
The U.S. Food and Drug Administration recommends that post-menopausal women who take hormone therapy for hot flashes or vaginal dryness use the lowest possible dose for the shortest possible time.
SOURCE: Journal of the American Medical Association, January 7, 2003.
Ultimi Articoli
Il Premio Strega 2026 arriva in tutta Roma con la finale in Campidoglio
Crans-Montana, Regione Lombardia ieri si è costituita parte civile per il rogo del locale Le Constellation
Coca-Cola Pizza Village 2026, a Pozzuoli sei giorni tra pizzerie, musica e incontri
IPRN Awards 2026, i trofei firmati Università di Parma tra AI e design
FDA approva la prima terapia genica per bambini con anemia falciforme dai 2 anni
Teatri OSCAR e ANGELI il cartellone della stagione 2026 -27
Lecco Film Fest 2026, quattro giorni “con tutte le sue creature” tra cinema, territorio e nuove generazioni
Diritti Umani - L’Università di Parma entra nella rete Scholars at Risk per la tutela della libertà accademica
Premio Ombudsman 2026, riconoscimento alle istituzioni UE e a Europol per trasparenza e sicurezza digitale